Drug Transporters

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation

Perspectives From the International Transporter Consortium Introduction Transporter studies are performed at various stages of drug development ‒ discovery to first-in-human (FIH) phase (in-vitro substrate and inhibition [...]

2019-08-20T12:39:25-04:00August 20, 2019|Categories: AbsorbThis Blog, Drug Transporters|

Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition

Introduction P-glycoprotein (P-gp) is a drug transporter recommended by regulatory agencies for in-vitro and in-vivo DDI evaluation. Due to high inter-laboratory variability in in-vitro P-gp data, regulators [...]

2019-07-18T15:00:45-04:00July 18, 2019|Categories: AbsorbThis Blog, Drug Transporters|Tags: , , |

Metformin Clinical DDI Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision

Introduction Metformin is an orally administered drug prescribed for the treatment of Type 2 diabetes. It is known to decrease hepatic glucose production, by inhibiting gluconeogenesis, and [...]

Transporters In Drug Development Based On Recent ITC Recommendations

Introduction Transporters are membrane proteins highly expressed in various organs of humans. They play a pivotal role in the absorption and disposition of both endogenous and exogenous [...]

Webinar: State of the Art in Clinical Transporter DDI Evaluation

Webinar Download Originally Hosted: Thursday, June 13, 2019 11:30am - 12:30pm EDT State of the Art in Clinical Transporter DDI Evaluation This presentation summarized the state-of-the-art in [...]

2019-10-09T12:33:18-04:00May 28, 2019|Categories: Drug Transporters, Webinars|Tags: , , |